Hikma Pharmaceuticals PLC - Back to Homepage

Keep yourself updated about Hikma

News Search

Search for a news item according to period of time or category.

Ensuring the Sustainability of our Business

Download Hikma's latest CR Report

18 May 2015

Hikma Founder and Honorary Life President Samih Darwazah passes away

London, 18 May 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceuticals company, is deeply saddened to announce that Samih Darwazah, Hikma’s Founder and Honorary Life President, passed away peacefully on Friday, 15 May, in London at the age of 85.

London, 18 May 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceuticals company, is deeply saddened to announce that Samih Darwazah, Hikma’s Founder and Honorary Life President, passed away peacefully on Friday, 15 May, in London at the age of 85. Mr. Darwazah was a politician, a philanthropist, an entrepreneur and a business leader that founded Hikma, a company that recently entered the FTSE100 index and now employs 7,000 people bringing affordable medicines to the world.

Mr. Darwazah founded Hikma in 1978 in Amman, Jordan.  His vision was to bring high quality and affordable medicines to the world.  With the help of his children, who joined the business in its early days, Hikma grew from a small factory in Jordan into the largest regional supplier of pharmaceuticals in the Middle East and North Africa (“MENA”) region.  The company also expanded outside the MENA region, establishing successful operations in Europe and the United States.  Today Hikma operates in around 50 countries, selling a broad range of branded generics, generic injectables, non-injectable generics and in-licensed patented products.  In 2005, the company floated on the London Stock Exchange and in March 2015 it entered the FTSE 100 index.

Mr. Darwazah was born in Nablus in 1930. One of several children, his family lived in Jaffa, where his father was a merchant, for most of his childhood. In 1948, the Darwazah family left their ancestral home and moved to Jordan.  Mr. Darwazah went to study at the American University of Beirut (“AUB”), where he met and married his wife, Samira, a fellow AUB student.  After obtaining a B.Sc. Degree in Pharmacy in 1954 and working for a few years in pharmacy in Jordan and Kuwait, Mr. Darwazah was offered a Fulbright Scholarship and went to study at the St. Louis College of Pharmacy in Saint Louis, Missouri.

A couple of months after receiving his master’s degree in Industrial Pharmacy, Mr. Darwazah signed on with Eli Lilly. He worked for the company from 1964 to 1976, first in the United States then in various positions in the Middle East marketing division. At the age of 48, after 12 years working for Eli Lilly and with extensive experience in marketing and management, Mr. Darwazah decided to return to Jordan and establish his own company – and Hikma was born.

As an entrepreneur and business leader, Mr. Darwazah became an influential figure in Jordan, creating jobs and developing a vibrant local pharmaceutical industry. He believed strongly that he had a responsibility to invest in local communities and he became a strong advocate of corporate responsibility.  In 1995, Mr. Darwazah was invited by Jordan’s Prince Zeid Ben-Shaker to serve as Minister of Energy and Mineral Resources to the late King Hussein. In later years, he was also a senator, served on the Advisory Economic Council to His Majesty the King of Jordan, and founded the Jordanian Trade Association. As a firm supporter of education and an advocate for women’s rights, Mr. Darwazah established a school for girls in Al Shoubak in Jordan in 2009, amongst many other philanthropic endeavours.

In recognition of Mr. Darwazah’s remarkable achievements as a businessman, Ernst and Young named him Middle East Entrepreneur of the Year in 2007. He was also the recipient of five honorary doctorates in recognition of his lifetime achievements – from The St. Louis College of Pharmacy, the Lebanese American University, Birzeit University, the American University of Beirut and the Jordan University of Science and Technology.

In addition to Mr. Darwazah’s significant professional achievements, he will perhaps be best remembered by all who knew him as someone who valued family above all else.  He surrounded himself with his four children and his eleven grandchildren.  The supportive “family” culture at Hikma thrives today, ten years after becoming a public company.  He will be sorely missed and always remembered by all who knew him.

Condolences can be sent to condolences@hikma.com

--  ENDS  --

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Baker, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0) 20 7399 2768/
+44 7771 665277
FTI Consulting  
Ben Atwell/ Matthew Cole                 +44 (0)20 3727 1000

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa ("MENA") and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. 

Press Release
+ more
Print page

Corporate

14 May 2015

Hikma AGM Trading Update

London, 14 May 2015 – Hikma Pharmaceuticals PLC (“Hikma” or “the Group”)(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, will hold its Annual General Meeting today where the following statement will be made regarding its current trading.

London, 14 May 2015 – Hikma Pharmaceuticals PLC ("Hikma” or "the Group”)(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, will hold its Annual General Meeting today where the following statement will be made regarding its current trading.  

Hikma has made a good start to the year and we are very pleased to reiterate our guidance for 2015 for the Group overall and for each of our business segments.

Group
We continue to expect full year Group revenue growth of around 6% in constant currency, following an extremely strong year in 2014, in which profit attributable to shareholders increased by 30%.  On a reported basis, we expect full year Group revenue growth of around 2%, reflecting foreign exchange rate movements in the year to date.  For the first half, we expect Group revenue in constant currency to be broadly in line with the same period last year.

Injectables
Our US Injectables business is performing well, with strong sales of certain products offsetting increased competition on other products.  We are making good progress transferring the products acquired from Bedford Laboratories in 2014 to our manufacturing facilities in New Jersey, Germany and Portugal and we recently launched the first of these products, CAFCIT® Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL). Management changes in our MENA Injectables business are delivering good results, especially in Algeria and Saudi Arabia, and in Europe revenue is stable.  Following the excellent performance in 2014, we remain on track to sustain 2015 global Injectables revenue at the same level as 2014 for both the half year and the full year, with a robust adjusted operating margin of around 35% after the dilution from Bedford R&D costs. 

Branded
Our Branded business is performing well.  Growth in the year to date is being driven by a recovery in Algeria and good demand in Saudi Arabia and the other GCC markets.  We expect continued growth in Branded sales across our markets, driven by new product launches and our focus on enhancing our product mix.  We continue to expect full year Branded revenue growth in the low teens and an improvement in adjusted operating margin of around 200 basis points, on a constant currency basis.  Taking into account exchange rate movements since the beginning of 2015, and assuming these rates prevail, we continue to expect reported Branded revenue growth in the high single digits and a slight improvement in adjusted operating margin.  As in previous years, we expect revenue to be stronger in the second half, reflecting the usual seasonality of this business. 

Generics
We are seeing strong demand for the legacy products in our Generics business and are benefitting from the contribution of certain market opportunities, albeit at a much lower level than in the previous two years, as anticipated.  We continue to expect sales from recent product launches to accelerate in the second half of the year and are therefore reiterating our guidance for full year Generics revenue of around $200 million in 2015.

Financing
We continue to have a very strong balance sheet, which gives us the financial capacity to pursue acquisition opportunities across our businesses.  On 1 April 2015, we further strengthened our financing capabilities when we successfully completed our first bond issuance – a $500 million 4.25% eurobond due April 2020.  The proceeds will be used to refinance existing debt and for general corporate purposes.  We now expect interest expense in 2015 will be around $54 million, up from our previous guidance of around $40 million, taking into account incremental interest costs and associated transaction fees.

Said Darwazah, Chairman and Chief Executive Officer of Hikma said:

"Hikma has made a good start to the year. We have performed well in each of our businesses following an extremely strong 2014, and we are pleased to be reiterating our 2015 guidance for the Group overall and for each of our business segments.

Over the longer-term, we are confident in our ability to continue to drive strong growth across the Hikma Group. By strengthening our operations in the MENA region, enhancing and expanding our global Injectables business and developing our non-injectable Generics portfolio in the US, we are building an extremely robust set of businesses that are uniquely positioned to capture a range of attractive future growth opportunities."

We will announce our interim results for the six months to 30 June 2015 on 19 August 2015.

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Baker, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0) 20 7399 2768/
+44 7771 665277
FTI Consulting  
Ben Atwell/ Matthew Cole                 +44 (0)20 3727 1000

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: "Injectables”, "Branded” and "Generics”, based principally in the United States, the Middle East and North Africa ("MENA") and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.

Press Release
+ more
Print page

Corporate

12 May 2015

Hikma launches caffeine citrate injection, commercialising the first of the Bedford products

London, 12 May 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces it has launched CAFCIT® Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL). CAFCIT® is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.

London, 12 May 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces it has launched CAFCIT® Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL).  CAFCIT® is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.

Said Darwazah, Chairman and CEO of Hikma said, “This is our first launch from the Bedford portfolio acquired last year.  We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities."

According to IMS Health, sales of caffeine citrate injection in the US market were approximately $7.6 million for the 12 months ending March 2015.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/
+44 7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa ("MENA") and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million.

Press Release
+ more
Print page

Product

11 March 2015

Hikma Pharmaceuticals Preliminary Results

Hikma Pharmaceuticals PLC (“Hikma”, “Group”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today reports its preliminary results for the year ended 31 December 2014.

Hikma Pharmaceuticals PLC (“Hikma”, “Group”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today reports its preliminary results for the year ended 31 December 2014.

Press Release
+ more
Print page

Corporate

04 March 2015

Notice of Prelim Results Announcement – Analyst Presentation

Notice of Prelim Results Announcements 2014. A presentation and webcast for analysts will take place at 9:30am GMT at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.

Notice of Prelim Results Announcements 2014. A presentation and webcast for analysts will take place at 9:30am GMT at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.

Wednesday 11 March 2015

9.30am (London time)/ 11.30am (Jordan time)

FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. (PLEASE NOTE NEW ADDRESS)

To join via conference call please dial: +44 (0) 20 3003 2666
UK Toll-Free Number: 0808 109 0700

Alternatively you can listen live via our website: www.hikma.com or www.cantos.com

Playback facility:
A playback of the conference call will be available via our website later that www.hikma.com

Press Release
+ more
Print page

Corporate

26 February 2015

Hikma signs exclusive license agreement with Azanta for Nimoral

London, 26 February 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the signing of an exclusive license agreement with specialty pharmaceutical company Azanta A/S for its proprietary cancer product Nimoral (nimorazole). Nimoral is a hypoxic radiosensitizer to enhance the effect of radiotherapy in head and neck cancer patients. The product is currently in Phase 3 clinical development and is being made available under named patient programs throughout the world.

London, 26 February 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the signing of an exclusive license agreement with specialty pharmaceutical company Azanta A/S for its proprietary cancer product Nimoral (nimorazole). Nimoral is a hypoxic radiosensitizer to enhance the effect of radiotherapy in head and neck cancer patients. The product is currently in Phase 3 clinical development and is being made available under named patient programs throughout the world.

Under the terms of the agreement, Hikma will have the exclusive rights to register, manufacture, distribute and market Nimoral in 20 markets in the MENA region including Turkey, leveraging Hikma’s strong local presence and regulatory expertise, with over 1,800 sales and marketing reps across the region.

Mazen Darwazah, Hikma’s Vice Chairman and CEO of MENA and Emerging Markets said, “Hikma is committed to improving the treatment of cancer in the MENA region through the development of our oncology product portfolio.  This partnership gives us access to a novel, oral anticancer treatment with excellent potential and reinforces our commitment to growing our portfolio through strong partnerships.  We look forward to the Phase 3 results for Nimoral and we are very pleased to be working with Azanta to bring this critically needed therapy to the MENA region.”

Dr. Claus Møller, Chief Executive Officer of Azanta, commented: "We are very pleased to enter this significant agreement with Hikma.  We believe Hikma will be an excellent partner for us for Nimoral in the MENA region, which has a population of more than 380 million people or 6% of the world population.  We will immediately begin transferring our technology to Hikma to enable them to provide Nimoral to patients in MENA.”

-- ENDS --

About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

About Azanta A/S
Azanta A/S is a privately owned Danish specialty pharma company primarily operating within oncology, women´s health and addiction medicine.  The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products.  Azanta A/S currently markets or makes available a string of specialty pharmaceutical products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy, and Angusta for labour induction.  In addition, Azanta A/S has a portfolio of low risk development projects for commercialisation within the near future.  For further information, please visit www.azanta.com.

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate
Strategy and Directors
of Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
Lucinda Henderson, Deputy
Director of Investor Relations
+44 (0)20 7399 2765/ +44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000
Press Release
+ more
Print page

Corporate

16 February 2015

Hikma Pharmaceuticals First Jordanian Site to Receive ISO 50001 Certification

Amman, 16 February 2015 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announced that it has attained the ISO 50001 certification in recognition of its dedication to improving its energy management system (EnMS) over the past three years for its Jordan manufacturing operations.

Amman, 16 February 2015 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announced that it has attained the ISO 50001 certification in recognition of its dedication to improving its energy management system (EnMS) over the past three years for its Jordan manufacturing operations.

This achievement positions Hikma as the first pharmaceutical company in the Middle East and the first Jordanian site to obtain the ISO 50001 certification, which enables organizations to continually enhance energy performance, efficiency, use and consumption. The certification was granted following a comprehensive on-site inspection and thorough evaluation process covering Hikma’s energy management documents, procedures and upcoming strategy for 2015. In addition to the ISO 50001 for energy management, Hikma had previously attained the ISO 9001 for quality management, ISO 14001 for environmental management, as well as the OHSAS 18001 for occupational health and safety.

Furthermore, Hikma periodically reports on various gas emissions and environmental outputs to demonstrate how it is improving its impact on the environment and aligning its operations to international standards. These reports are submitted to global entities such as the United Nations Global Compact, Carbon Disclosure Project and Global Reporting Initiative.

Mazen Darwazeh, Vice Chairman, President and CEO, MENA and Emerging Markets of Hikma said: “Being the first Jordanian site to receive the ISO 50001 certification is a distinct honor that spurs us to do all that is in our power to ensure that Hikma continues to carry out eco-friendly operations,” commented. “Over the past few years, we have been wholly committed to mitigating our energy consumption and gas emissions to reduce our ecological footprint in line with global best practices. By doing so, we have succeeded in establishing an internal culture at Hikma that promotes environmental sustainability and conscientiousness.”

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Hana Ramadan, Director of Corporate Communication +962 6 5802900 ext. 313
Dana Shekem, Marketing Communication Specialist +962 6 5802900 ext. 356

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenues of $918 million and a profit attributable to shareholders of $80.3 million. By December 2014, Hikma employed a total of 7,250 staff members worldwide.

Press Release
+ more
Print page

Corporate

27 January 2015

Hikma partners against corruption and supports MENA growth markets at WEF

Amman, 27 January 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, joined the 45th World Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland, held on January 21 - 24, 2015, to provide insights on the impact of recent societal, political and economic developments on growth markets in the Arab World. Serving as a WEF Regional Associate for the second consecutive year, Hikma was one of 2,540 business, government, academic and civil society leaders to convene this year to explore solutions for pressing international, regional and industry issues within ‘The New Global Context' - the Forum's theme - as brought on by breakthrough technologies, demographic shifts and political transformations.

Amman, 27 January 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, joined the 45th World Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland, held on January 21 - 24, 2015, to provide insights on the impact of recent societal, political and economic developments on growth markets in the Arab World. Serving as a WEF Regional Associate for the second consecutive year, Hikma was one of 2,540 business, government, academic and civil society leaders to convene this year to explore solutions for pressing international, regional and industry issues within ‘The New Global Context' - the Forum's theme - as brought on by breakthrough technologies, demographic shifts and political transformations.

Representing Hikma, Mazen Darwazeh, Vice Chairman, President and CEO of MENA and Emerging Markets, participated as a discussion leader in the ‘Arab World Growth Markets' session alongside Jordan's Minister of Finance, Umayya Toukan; the Palestinian National Authority's Deputy Prime Minister and Minister of Economy, Mohammad Mustafa; and Dana Gas PJSC's CEO, Patrick Allman-Ward. During the session, Darwazah elaborated on the economic consequences of falling oil prices; the potential of cross-sector and public-private integration; as well as the need for greater investment in, and Hikma's contribution to, talent and education development.

"Public-private and international cooperation is key to ensuring the sustainable growth of worldwide economies in the face of significant oil price shocks, geopolitical tensions and the persistent gap in scientific, technical and human skills," said Darwazeh. "As a rapidly-growing multinational group with markets in more than 50 countries, Hikma is committed to helping communities boost their resilience and adaptability to societal, political and commercial changes, a vision that is reflected in our partnership with the WEF."

+ more
Print page

CR

Get adobe reader Most computers will open PDF documents automatically, but you may need to download Adobe Reader.